Nonalcoholic Steatohepatitis (NASH) Market

1
How profitable is it to invest in NASH market?
2
75 Pages Report
Published Date Aug - 2014
3
Introduction
Table of Content

• Introduction
• Executive Summary
• Global 3D Technology Market Overview
• Global 3D Technology Market by Products
• Global 3D Technology Market by Applications
• Global 3D Technology Market by Geography
• Company Profiles

Key Audiences
Scope of the Report
Key Benefits
4
Description
Nonalcoholic Steatohepatitis (NASH) also known as
silent disease is a type of fatty liver
disease, which mainly affects people with
diabetes and obesity. Symptoms of NASH are found
among all demographics (from children to adults)
however, they are more prevalent in younger
people. Corner stage of cirrhosis is a form of
NASH that can be reversed with proper medication.
Moreover, most of the NASH specific
pharmaceutical solution are in clinical trial
phase . Additionally, the absence of efficient
diagnostic technologies acts as a major hurdle
for the research of NASH therapeutics.
Nevertheless, the emergence of novel biomarker
technologies and improvements in liver biopsy
technologies are expected to bring about an
evolution in the diagnosis of NASH and other
fatty liver diseases. Global non-alcoholic
Steatohepatitis market is expected to garner
1693.2 million by 2020 growing at a CAGR of
25.6 during 2014-2020. Increase in cycles of
clinical trials and their success rate has
increased the probability of industries receiving
commercial approval for NASH therapeutics by the
end of 2017. The market growth is restricted by
factors such as NASHs complex and enigmatic
physiological structure and inefficient
diagnostics technology these factors could also
prolong the commercialization process for NASH
therapeutics.
5
KEY BENEFITS

• Various opportunities for non alcoholic fatty
  liver disease therapeutics present in developed
  as well as developing economies are thoroughly
  assessed
• Substitute treatments and their potential impact
  on NASH therapeutics are strategically quantified
  in the report
• Opportunities from a business perspective latent
  in the Asia-Pacific region are brought to light
• Market dimensions of diagnostic techniques used
  in NASH monitoring provide a clear outline of the
  NASH therapeutics research market
• Geography-wise segmentation of clinical trials is
  conducted to provide strategic intelligence to
  the stakeholder
• Pipeline analysis for the key NASH therapeutics
  under clinical research provides market
  intelligence needed for commercialization
• Detailed analysis of market dynamics provides
  intelligence about market competencies according
  to segments
• In depth analysis of key players operating in the
  fatty liver disease therapeutics market is
  conducted according to regions

6
Table of Contents

• Introduction
• Executive Summary
• Market Beyond What To Expect By 2025
• Market Overview
• 5. Global Nonalcoholic Steatohepatitis Market By
  Drug Types
• 6. Global Nonalcoholic Steatohepatitis Market
• 7. Company Profiles

7
Nonalcoholic Steatohepatitis Market Overview

Market Definition
  Key Findings


Impeding opportunities for NASH
 Other
Nonalcoholic Steatohepatitis Market Overview
Incongruity about preventative role of Fructose
Diagnostic Techniques
Prevalence of nonalcoholic fatty liver disease
Dos and Donts For Nonalcoholic Fatty Liver
Disease
8
Market Dynamics
Your feedback is important to us
What would you like to know more about this Study
?

• Global Industry Analysis
• Market Size
• Market Share
• Market Trends
• Opportunities and Forecast

Market Drivers
Rampant rate of obesity and diabetes globally
Acceleration in initiatives for research and
development activities
Market Restraints
Blurred understanding of pathophysiology of NASH
Please inform us on http//www.alliedmarketresea
rch.com/contact-us
Inefficient diagnostic technology for NASH
9
Global Nonalcoholic Steatohepatitis Market By
Drug Types
GFT505
Obeticholic Acid (INT-747)
Global Nonalcoholic Steatohepatitis Market By
Drug Types
Simtuzumab and Liraglutide (Victoza)
Vitamin E
Poglitazone
10
Top Market Players of Nonalcoholic
Steatohepatitis (NASH) Market 

• Genfit.
• Gilead Science
• Novo Nordisk
• Intercepts Pharmaceuticals
• Enzo Biochem, Inc.
•  Raptor Pharmaceutical Corp.

11
Your feedback is important to us
What would you like to know more about this Study
?

• Global Industry Analysis
• Market Size
• Market Share
• Market Trends
• Opportunities and Forecast

Please inform us on http//www.alliedmarketresea
rch.com/contact-us
12
http//www.alliedmarketresearch.com/nonalcoholic-s
teatohepatitis-NASH-market